Today we announce our results for the financial year to 30 April 2021.
The firm has seen a 12% increase in UK revenue to £175.5m and a 23% increase in UK profit to £71m. UK profit per equity partner is 18% up on last year.
UK Managing Partner, Shane Gleghorn, said: "Our focus this financial year has been our people and clients, and these pleasing results are attributable to their commitment to the firm. We anticipated, and had, a slow start to our financial year due to the contraction caused by the onset of the pandemic. We were confident, however, that the focus of our sector and…
Cambridge, UK, 15 July 2021 – PharmEnable, an AI drug discovery company unlocking challenging biological targets, announces that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to apply their respective technologies and expertise to discover novel oral antiviral drugs with activity against coronaviruses.
The COVID-19 pandemic has not only demonstrated the threat that novel and variant viruses pose, but also the vital role of innovative science to develop vaccines and drugs to combat infection, improving patient health while…
AMSBIO has established an unmatched commercial biorepository and procurement network that includes a large selection of fully characterized and annotated Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks to help streamline your research.Drawing upon decades of experience - AMSBIO is able to offer an extensive collection of frozen and paraffin-embedded (FFPE) human and animal tissue samples from normal and many diseased tissue types. All FFPE tissue blocks are processed using standard clinical procedures, under Institutional Review Board (IRB) approved protocols. Each tissue…
The Biosphere, a specialist lab facility on Newcastle Helix is hosting an online careers event aimed at graduates and postgraduate research students who are looking to make the transition from academia to industry.
The event will see representatives from a range of companies who are based in The Biosphere. They will share their own experiences, personal journey, top tips, and industry insight. They will also showcase some of the exciting job opportunities available to those looking to base themselves in North East.
Businesses who will be sharing their expertise include Newcells Biotech, 3D…
Today we announce the completion of our permanent office space in the Edward Pavilion building in Liverpool's vibrant and iconic Royal Albert Dock.
The completion of the project follows the signing of a ten-year lease in February 2020 and underlines our long-term commitment to the city and its communities.
Since establishing a presence in Liverpool in November 2018, the firm has built a team of 100+ legal and business experts, and has a growing reputation as an employer of choice for outstanding talent in the region.
Our office in Liverpool focuses on delivering a broad range of legal…
We have advised the Global EdTech startup, Unibuddy on its US$20 million Series B investment.
Unibuddy is the number one peer-to-peer university recruitment platform that has helped 770,000 students from over 180 countries make better decisions about their higher education journey. The platform works with 450+ higher education institutions worldwide, from the University of Cambridge (UK) and the University of Southern California (US) to Taylor’s University (Malaysia) and Bond University (Australia).
Unibuddy has raised a total of US$32 million since its inception in 2017. It is focused on…
Stevenage, UK, 7 July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional £20 million in a Series B2 financing round.
Having demonstrated proof of efficacy in patients with refractory or unexplained chronic cough[i], NeRRe will now continue the clinical development of orvepitant in chronic cough caused by IPF, a rare type of interstitial lung disease[ii]. A dominant…
UK Life Sciences Vision sets 10-year strategy for sector to solve some of the biggest healthcare problems of our generation, including cancer and dementia.
- UK Life Sciences Vision sets 10-year strategy for sector to build on successes of COVID-19 response and accelerate delivery of innovations to patients- mission-led approach to solve some of the biggest healthcare problems of our generation, including cancer and demential- aunch of Life Sciences Investment Programme brings total amount of funding available to UK’s most promising life sciences companies to £1 billion
The remarkable…
Tokyo, Japan, and Cambridge, UK, 6 July 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design and development, and InveniAI® LLC (“InveniAI,” Guilford, CT, USA), a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today the initiation of a new R&D collaboration.
The objective of the collaboration is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can…